Pfiz­er teams up with Sinopharm to mar­ket 12 new drugs in Chi­na — re­port

Pfiz­er and Chi­na-based Sinopharm Group have teamed up to seek ap­proval for 12 new drugs in Chi­na through 2025, Reuters re­port­ed Thurs­day.

Pfiz­er agreed to a strate­gic co­op­er­a­tion agree­ment with the state-owned Sinopharm on Wednes­day, with Sinopharm Pres­i­dent Liu Yong say­ing the agree­ment will ac­cel­er­ate the de­liv­ery of Pfiz­er’s new drugs to pa­tients, Reuters re­port­ed.

The deal builds on Pfiz­er’s re­cent part­ner­ships in Chi­na, with state-owned Mehe­co agree­ing to im­port and dis­trib­ute its Covid-19 an­tivi­ral Paxlovid through next No­vem­ber, as well as an­oth­er 5-year deal with Zhe­jiang Hua­hai signed last Au­gust to pro­duce and sell Paxlovid too.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.